Matoke® Pharma Executive Team

Alan Westwood

Managing Director, Pharma Division

Alan worked for Bayer Pharmaceuticals in clinical development, sales and marketing. For the last 25 years he was responsible for Bayer’s Global anti-infective portfolio and oversaw the global strategic marketing for products such as Ciprofloxacin and Avelox, the in-licensing and strategic development of two Phase 3 antibiotics and the launch of a third in emerging markets. Involved in many new antibiotic evaluations, Alan has developed a broad network of international leaders in the anti-infective field.

Dr Penny Ansell

Project Direction

Dr Penny Ansell is an independent senior clinical research executive with over 25 years’ experience in international pharmaceutical R&D. Her industry experience includes Bayer, Marion Merrell Dow, Ferring Pharmaceuticals and uniQure NV. She has specific experience in international clinical research, coupled with broad regulatory knowledge and extensive project management experience.

Wendy Richings Barrow

Consultant, Regulatory Affairs and Pharmaceutical Development

Wendy Richings Barrow (founder of Subiaco Associates Ltd.) is a scientist with over 30 years’ experience in new product development and regulatory affairs. Her industry experience includes Smith, Kline & French, Glaxo Animal Health and American Cyanamid Ltd., and she has experience with small, start-up companies, multi-national pharmaceutical, natural healthcare and biotech companies. Wendy has an in-depth knowledge of regulatory affairs and pharmaceutical development.

Dr Ian Harding

Consultant, Research & Development

Dr Ian Harding (President and Co-Founder, the Micron Group) is a pharmaceutical scientist with over 30 years’ experience in drug development. His industry experience includes Bayer and Marion Merrell Dow and the Micron Group has experience with many client companies from blue chip pharmaceuticals to biotech companies. Ian has expertise in many therapeutic areas and specialises in anti-infectives. He has published widely in the field of Infectious Diseases and is a specialist in the design, management and reporting of resistance surveillance studies and clinical trials.

Dr Miriam O’Hare

Consultant, Clinical Development

Dr Miriam O’Hare (Co-Founder, the Micron Group) is a microbiologist with more than 20 years’ experience in international pharmaceutical R&D. She has extensive clinical development experience obtained in both pharmaceutical and CRO companies, and an in-depth knowledge of development of anti-infectives. She is a named author on over 90 peer reviewed publications and has written over 50 clinical trial reports and associated Regulatory Authority documents. Miriam is an Associate Member of the Royal College of Pathologists in London and a Fellow of the Royal Society of Medicine.

Mark Hansen

Commercial Officer

Mark has over 30-years’ experience in the healthcare industry, involving both the industry and service sectors. With a core background in pharmaceutical marketing and product development, he has particular expertise in anti-infectives, immunology, and respiratory/pulmonary medicine. Mark’s background also includes general management, business development, sales management and organizational leadership at many levels.